

UK National Guideline for the Management of Gonorrhoea in Adults 2011

**Clinical Effectiveness Group
British Association for Sexual Health and HIV**

Guideline Development Group:

Dr Chris Bignell (lead author) and Dr Mark FitzGerald (lead editor on behalf of BASHH)

Date of writing : June 2011

Review date : 2016

Changes since 2005 Guideline

- Nucleic Acid Amplification Tests (NAATs) can be used for both anogenital and pharyngeal specimens. Supplementary testing is required for reactive tests from low prevalence populations and for specimens from the rectum or pharynx.
- First-line treatment is now Ceftriaxone 500 mg IM stat plus Azithromycin 1g p.o stat
- Test of cure is recommended for all cases
- A patient information leaflet is available (see website)
- There is a link for reporting cephalosporin treatment failures to the HPA

Introduction

The main purpose of this guideline is to offer recommendations on the diagnosis, treatment and health promotion principles for the effective management of anogenital and pharyngeal gonorrhoea. It is aimed primarily at people aged 16 years and older presenting to services offering level 3 care in STI management within the United Kingdom. However, the principles of the recommendations could be adopted at all levels.

Editorial independence

This guideline was commissioned and edited by the Clinical Effectiveness Group (CEG) of the British Association for Sexual Health and HIV (BASHH). No external funding was sought or obtained.

Rigour of development

This guideline was produced according to specifications set out in the CEG's 2010 document "Framework for Guideline Development and Assessment" outlined at bashh.org/guidelines. This guideline has been updated by reviewing the previous gonorrhoea guideline (2005) and medical literature since its publication. A MEDLINE search was done of published articles in any language for the years 2005-2009 using the subject headings 'gonorrhoea' and '*Neisseria gonorrhoeae*'. All entries in the English language or with abstracts in English were viewed because of the paucity of 'clinical trials' or 'reviews'. The Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effectiveness, and Cochrane Controlled Trials Register were reviewed using the textword 'gonorrhoea' and all entries considered. Abstracts from meetings in the relevant period were handsearched and considered. The draft guideline was appraised with the AGREE instrument, posted on the BASHH website for a consultation period of 3 months, and piloted in a sample of clinics. In response to the consultation a number of changes were made, which are supported by more recent references.

Aetiology

Gonorrhoea is the condition of being infected with the Gram-negative diplococcus *Neisseria gonorrhoeae*. The primary sites of infection are the mucous membranes of the urethra, endocervix, rectum, pharynx and conjunctiva. Transmission is by direct inoculation of infected secretions from one mucous membrane to another.

Clinical features.

Symptoms.¹⁻³

Men :

- urethral infection commonly causes urethral discharge (>80%) and/or dysuria (>50%), starting within 2-5 days of exposure.
- urethral infection can be asymptomatic (<10%).
- rectal infection is usually asymptomatic but may cause anal discharge (12%) or perianal/anal pain or discomfort (7%).
- pharyngeal infection is usually asymptomatic (>90%).

Women:

- infection at the endocervix is frequently asymptomatic (up to 50%).
- increased or altered vaginal discharge is the commonest symptom (up to 50%).
- lower abdominal pain may be present (up to 25%).
- urethral infection may cause dysuria (12%) but not frequency.
- gonorrhoea is a rare cause of intermenstrual bleeding or menorrhagia.
- rectal infection more frequently develops by transmucosal spread of infected genital secretions than from anal intercourse and is usually asymptomatic.
- pharyngeal infection is usually asymptomatic (>90%).

Neisseria gonorrhoeae may co-exist with other genital mucosal pathogens, notably *Chlamydia trachomatis*, *Trichomonas vaginalis*, and *Candida albicans*. If symptoms are present, they may be attributable to the co-infecting pathogen.

Signs.^{1,2}

Men:

- a mucopurulent or purulent urethral discharge is commonly evident.
- rarely, epididymal tenderness/swelling or balanitis may be present.

Women:

- mucopurulent endocervical discharge and easily induced endocervical bleeding (<50%). [Note: mucopurulent endocervical discharge is not a sensitive predictor of cervical infection (<50%).]
- pelvic/lower abdominal tenderness (<5%).
- commonly, no abnormal findings are present on examination.

Complications.

Transluminal spread of *N. gonorrhoeae* from the urethra or endocervix may occur to cause epididymo-orchitis or prostatitis in men and pelvic inflammatory disease in women. Haematogenous dissemination may also occur from infected mucous membranes to cause skin lesions, arthralgia, arthritis and tenosynovitis (disseminated gonococcal infection). There are no recent studies quantifying the risk of developing complicated gonococcal infection but reporting from GU Medicine clinics in the UK indicate they are uncommon⁴.

Diagnosis

- This guideline should be read in conjunction with Health Protection Agency 'Guidance for Gonorrhoea Testing in England and Wales' (2010) and BASHH guidelines on testing for STIs/ gonorrhoea^{5,6}.
- The diagnosis of gonorrhoea is established by the detection of *N. gonorrhoeae* at an infected site.
- The approach and method used to test for gonorrhoea will be influenced by the clinical setting, storage and transport system to the laboratory, local prevalence of infection and the range of tests available in the laboratory.
- No test for gonorrhoea offers 100% sensitivity and specificity^{5,7,8,9}.
- Microscopy (x1000) of Gram stained genital specimens allows direct visualization of *N. gonorrhoeae* as monomorphic Gram negative diplococci within polymorphonuclear leukocytes. It offers good sensitivity (90-95%) in

men with urethral discharge and is recommended to facilitate immediate diagnosis in symptomatic men (level of evidence III; grade C recommendation). Microscopy of urethral smears in asymptomatic men is less sensitive (50-75%)¹. Microscopy should be done on men with rectal symptoms. In women, microscopy has poor sensitivity for the identification of gonococcal infection - 37-50% for endocervical smears and 20% for urethral smears². Microscopy is not recommended for urethral smears in women or for detecting asymptomatic rectal infection because of low sensitivity (level of evidence III; grade C recommendation). Microscopy is not appropriate for diagnosing gonorrhoea in pharyngeal specimens.

- Detection of *N. gonorrhoeae* can be achieved by nucleic acid amplification tests (NAATs) or culture. NAATs are generally more sensitive than culture and offer testing on a wider range of specimen types^{5,8-12}. NAATs show high sensitivity (>96%) in both symptomatic and asymptomatic infection^{10,12}. They show equivalent sensitivity in urine and urethral swab specimens from men¹³ and in vaginal and endocervical swabs from women¹⁴. The test sensitivity in female urine is significantly lower and urine is not the optimal specimen in women^{5,12,15}, (level of evidence II; grade B recommendation).
- Persons undergoing testing for genital tract gonorrhoea are usually also tested for infection with *Chlamydia trachomatis*. NAATs are the standard test methodology for *C. trachomatis* testing and commercial tests offer dual capability to also test for *N. gonorrhoeae* on the same sample. When testing for genital tract infection, a dual NAAT for both pathogens maximizes sensitivity and operational ease of specimen collection, transport and processing.
- NAATs are significantly more sensitive than culture for detecting *N. gonorrhoeae* in the rectum and pharynx although are not yet licensed for use at these sites¹⁶⁻²⁰. Commercially available NAATs differ in their cross-reactivity to commensal *Neisseria* species which may be present at significant levels at these sites, particularly in the pharynx²¹. At present it is recommended that reactive specimens from the rectum and pharynx are confirmed by supplementary testing, ie using a different target. (level of evidence III; grade C recommendation)^{5,7,22}.
- Culture continues to offer a specific, sensitive and cheap diagnostic test at genital sites. It allows confirmatory identification and antimicrobial susceptibility testing, which is of increasing importance as antimicrobial resistance to *N. gonorrhoeae* continues to evolve. Selective culture media containing antimicrobials are recommended to reduce contamination²³ (level of evidence II; grade B recommendation).
- Whatever the testing approach adopted, positive test results should give a positive predictive value of >90%. In areas of low gonorrhoea prevalence the use of NAATs may require supplementary testing to confirm the diagnosis^{5,7,22}. Clinicians need to be familiar with the test performance of NAATs and be able to interpret results in their clinical setting^{24,25}.

Specimen collection.

Men:

A first pass urine is the preferred sample for NAAT testing ^{7,10,13,15}. Microscopy and culture require a urethral/meatal swab specimen. The collection and testing of rectal and pharyngeal swab specimens should be directed by sexual history, symptoms at these sites and also considered in men who receive oral-anal or digital-anal contact ²⁶.

Women:

Vaginal or endocervical swab specimens are equally sensitive for detecting *N. gonorrhoeae* by NAAT testing ¹⁴. Culture requires an endocervical and urethral swab specimen for maximum sensitivity. Urine is a suboptimal sample for the detection of *N. gonorrhoeae* in women ^{5,7,9,12,15}. The collection and testing of rectal and pharyngeal swab specimens should be directed by sexual history, symptoms at these sites and also considered in women who are sexual contacts of gonorrhoea.

- For culture, direct plating of genital samples and use of transport media with prompt laboratory plating both give acceptable results ²² (evidence level IV).
- Data is lacking on the sensitivity of a single set of tests to identify infection with *N. gonorrhoeae*. The use of a single endocervical or vulvovaginal NAAT sample will identify 90-95 % of women with gonococcal infection ^{2,27}. Women with *N. gonorrhoeae* infection often have infection at multiple sites ²⁸. A minority of MSM with gonorrhoea have infection at multiple sites, thus all exposed sites need sampling ¹⁸.
- To confidently exclude infection in patients who attend within three days of sexual contact, a second set of tests should be considered if epidemiological treatment with effective antimicrobial therapy is not given ²⁹ (evidence level IV, recommendation level C). Conventionally this would be 14 days after contact.

Management.

General Advice.

- Patients should be given a detailed explanation of their condition with particular emphasis on the long-term implications for the health of themselves and their partner(s). This should be reinforced with clear and accurate written information (level of evidence IV; grade C recommendation).
- Patients should be advised to abstain from sexual intercourse until they and their partner(s) have completed treatment (level of evidence IV; grade C recommendation); if azithromycin is used, this will be 7 days after treatment was given.

Further Investigation.

- A culture should be taken in all cases of gonorrhoea diagnosed by NAATs prior to antibiotics being given, if possible⁵, so that susceptibility testing can be performed and resistant strains identified.

- Screening for coincident sexually transmitted infections should routinely be performed in patients with or at risk of gonorrhoea (evidence level III, recommendation level C).

Treatment

Indications for therapy (level of evidence IV; grade C recommendation)

- Identification of intracellular Gram-negative diplococci on microscopy of a smear from the genital tract.
- a positive culture for *N. gonorrhoeae* from any site.
- a positive NAAT for *N. gonorrhoeae* from any site. Supplementary testing is recommended if positive predictive value of the test is < 90%^{5,7,21}.
- recent sexual partner (s) of confirmed cases of gonococcal infection.
- consider offering on epidemiological grounds following sexual assault.

Recommended treatment³⁰⁻³⁸

Uncomplicated anogenital infection in adults:

- Ceftriaxone 500mg IM as a single dose
with
Azithromycin 1g oral as a single dose
(level of evidence IV; grade C recommendation)
- *N. gonorrhoeae* has progressively exhibited reduced sensitivity and resistance to many classes of antimicrobials. Published trials of gonorrhoea treatment reflect clinical efficacy in past eras of antimicrobial sensitivity. Surveillance data in the England and Wales shows significant levels of *N. gonorrhoeae* resistance to penicillin (22% in 2009), tetracyclines (68% in 2009) and ciprofloxacin (35.3% in 2009)³⁹⁻⁴¹. High-level azithromycin resistance (MIC >256 mg/L) was observed in 2007 in the UK⁴². In 2009, decreased susceptibility to cefixime (MIC \geq 0.25mg/L) was observed at 1.2% and four isolates (0.3%) with decreased susceptibility to ceftriaxone (MIC \geq 0.125mg/L) were also identified⁴⁰. Three UK cases of clinical cefixime failure were reported in 2011^{43,44}.
Most resistant infections are acquired in the UK.
- The increasing recognition of multidrug resistant *N. gonorrhoeae* has been the driving force for the recommendation of extended spectrum cephalosporins as the preferred treatment of gonorrhoea⁴⁵. Concerns about the upward drift of resistance to cephalosporins⁴⁶ justify the increased dose of ceftriaxone now recommended.
- Azithromycin is recommended as co-treatment irrespective of the results of chlamydia testing (level of evidence IV, grade C recommendation), to delay the onset of widespread cephalosporin resistance⁴⁶. There is some in vitro evidence of synergy between azithromycin and cephalosporins⁴⁷, and improved eradication of pharyngeal gonorrhoea has been reported when azithromycin was combined with cephalosporin therapy⁴⁸.

Alternative regimens

Clinicians using alternative regimens for the treatment of gonorrhoea are recommended to regularly review local and national trends in gonococcal antimicrobial resistance.

All the agents below should be accompanied by Azithromycin 1g oral as a single dose.

- Cefixime 400mg oral as a single dose. (level of evidence 1b; grade A recommendation). Only advisable if an intramuscular injection is contra-indicated or refused by the patient
Observations in Asia have raised serious concerns over the adequacy of the 400mg cefixime for the treatment of genital tract gonorrhoea. Repeated treatment failures have been reported with cefixime and other oral extended spectrum cephalosporins^{45,49}.
- Spectinomycin 2g IM as a single dose. (level of evidence 1b; grade A recommendation)
Spectinomycin was not being manufactured in 2010 so may be difficult to obtain. See BASHH website for further details..
- Other single dose cephalosporin regimes, notably Cefotaxime 500mg IM as a single dose. (level of evidence Ib; grade A recommendation)
or Cefoxitin 2g IM as a single dose plus probenecid 1g oral. Alternative injectable or oral cephalosporins offer no advantage in terms of efficacy and pharmacokinetics over ceftriaxone or cefixime³⁴.
- Cefpodoxime is an alternative oral third generation cephalosporin that as a single dose of 200mg oral is licensed for the treatment of uncomplicated gonorrhoea⁵⁰. Published trial data are limited, but in view of its less favourable pharmacokinetics than cefixime and suboptimal efficacy against pharyngeal infection, it should be used with caution at a dose of 400mg. (level of evidence II; grade C recommendation).
- Quinolones cannot generally be recommended for the treatment of gonorrhoea because of the high prevalence of quinolone resistance worldwide^{40,41,51}. When an infection is known before treatment to be quinolone sensitive, ciprofloxacin 500mg orally as a single dose or ofloxacin 400mg orally as a single dose have proven efficacy (level of evidence Ib; grade A recommendation)^{37,52}.
- High dose azithromycin (2.0g as a single dose) has shown acceptable efficacy in clinical trials, but was associated with high gastrointestinal intolerance⁵³. The clinical efficacy of azithromycin does not always correlate with *in-vitro* sensitivity testing⁵⁴⁻⁵⁵ and high-level azithromycin resistance has been

observed in the UK⁴². A single dose of azithromycin 1.0g alone is not recommended as treatment for gonorrhoea (level of evidence II; grade C recommendation).

- The alternative treatment regimens listed do not comprise all effective treatment regimens, but reflect clinical practice in the UK.

Treatment of complicated infections

Gonococcal pelvic inflammatory disease (PID)

Ceftriaxone 500 mg IM stat
followed by oral Doxycycline 100 mg bd plus Metronidazole 400 mg bd for 14 days
(see PID guidelines www.bashh.org.uk)

Gonococcal Epididymo-orchitis

Ceftriaxone 500 mg IM plus Doxycycline 100 mg bd for 10-14 days
(see Epididymo-orchitis guideline www.bashh.org.uk)

Gonococcal Conjunctivitis

A 3 day systemic regime is recommended as the cornea may be involved and is relatively avascular (level of evidence IV, grade C recommendation)
The eye should be irrigated with saline/water

- Ceftriaxone 500 mg IM daily for 3 days
- For non-anaphylaxis allergy: Ceftriaxone as above
- If history of penicillin anaphylaxis or established Cephalosporin allergy:
Spectinomycin 2 g IM stat daily for 3 days
Or
Azithomycin 2 g oral stat
plus Doxycycline 100 mg bd for 1 week
plus Ciprofloxacin 250 mg daily for 3 days
(grade C recommendation, level of evidence IV)

Disseminated Gonococcal Infection (DGI) (grade C recommendation)

- Ceftriaxone 1g IM or IV every 24 hours
Or
Cefotaxime 1 g IV every 8 hours
Or

Ciprofloxacin 500 mg IV every 12 hours (if the infection is known to be sensitive)

Or

Spectinomycin 2g IM every 12 hours

- Therapy should continue for 7 days but may be switched 24-48 hours after symptoms improve to one of the following oral regimes:

Cefixime 400 mg twice daily

Or

Ciprofloxacin 500 mg twice daily

Or

Ofloxacin 400 mg twice daily

Allergy.

Third-generation cephalosporins such as cefixime and ceftriaxone show negligible cross-allergy with penicillins⁵⁶. Contraindications to the administration of ceftriaxone are hypersensitivity to any cephalosporin or previous immediate and/or severe hypersensitivity reaction to a penicillin or other beta-lactam drug⁵⁷. Recommended treatments for patients giving a history of such hypersensitivity:

- Spectinomycin 2g IM as a single dose (level of evidence Ib; grade A recommendation).

with

Azithromycin 1g oral as a single dose

or

- Azithromycin 2.0g oral as a single dose (level of evidence Ib; grade B recommendation)

or

- Ciprofloxacin 500mg orally as a single dose when the infection is known or anticipated to be quinolone sensitive.

Pregnancy and Breastfeeding.

Pregnant and breast-feeding women should not be treated with quinolone or tetracycline antimicrobials.

Azithromycin: manufacturer advises use only if adequate alternatives are not available.

Pregnancy does not diminish treatment efficacy.

Recommended Regimes⁵⁸⁻⁶⁰

- Ceftriaxone 500mg IM as a single dose.
with Azithromycin 1g oral as a single dose
(level of evidence IV; grade C recommendation)
- or
- Spectinomycin 2g IM as a single dose. (level of evidence Ib; grade A recommendation).
with Azithromycin 1g oral as a single dose

Pharyngeal infection.

Single-dose antimicrobials treatments have in general demonstrated lower efficacy ($\leq 90\%$) in eradicating *N. gonorrhoeae* from the pharynx than in eradicating genital infection^{31,61}. Failure has even been reported with ceftriaxone⁶²

Recommended treatments^{31,61}

- Ceftriaxone 500mg IM as a single dose with Azithromycin 1g as a single dose (level of evidence IV; grade C recommendation)
- or
- Ciprofloxacin 500mg orally as a single dose if *N. gonorrhoeae* known to be quinolone sensitive (level of evidence Ib; grade B recommendation)
- or
- Ofloxacin 400mg orally as a single dose if *N. gonorrhoeae* known to be quinolone sensitive. (level of evidence Ib; grade B recommendation).

Single dose treatment with spectinomycin has poor efficacy in eradicating gonococcal infection of the pharynx³¹.

HIV Infection

Treatment for gonorrhoea in HIV infected individuals is the same as in those who are HIV negative

Co-infection with *Chlamydia trachomatis*

Genital infection with *C. trachomatis* commonly accompanies genital gonococcal infection (35% of heterosexual men and 41% of women with gonorrhoea, GRASP 2008). Testing for *C. trachomatis* should routinely be performed on all adults with gonorrhoea or treatment given to eradicate possible co-infection^{29,38} (level of evidence IV; grade C recommendation).

Sexual partners.

Partner notification should be pursued in all patients identified with gonococcal infection, preferably by a trained health adviser in GU Medicine. Action and outcomes should be documented⁶³. Partner notification should follow national recommendations⁶⁴:

- Male patients with symptomatic urethral infection should notify all partners with whom they had sexual contact within the preceding 2 weeks or their last partner if longer ago.
- Patients with infection at other sites or asymptomatic infection should notify all partners within the preceding 3 months.

Sex partners should be offered testing and treated epidemiologically for gonorrhoea (level of evidence IV; recommendation level C).

Follow up and test of cure.

Assessment after treatment may be helpful (level of evidence IV; grade C recommendation):

- to confirm compliance with treatment,
- to ensure resolution of symptoms,
- to enquire about adverse reactions,
- to take a sexual history to explore the possibility of re-infection,
- to pursue partner notification and health promotion.

A test of cure (TOC) is now recommended in all cases (evidence level IV, grade C recommendation). This is a) to identify emerging resistance, which on past experience is likely to occur in due course⁴⁶ and b) because the susceptibility results that indicate potential failure to Ceftriaxone and Cefixime are not yet defined.

Where resource or practical considerations require TOC to be selective rather than universal, then the following patients should be prioritized –

- Persisting symptoms or signs
- Pharyngeal infection (all treatments are less effective at eradicating pharyngeal infection⁶¹)
- Treatment with anything other than the first-line recommendations

Method and timing of TOC. The current evidence is very scanty and the following is based on expert opinion and pragmatic considerations –

- Persisting symptoms or signs – test with culture, performed at least 72 hours after completion of therapy²³
- If asymptomatic - test with NAAT's where available followed by culture if positive. Test 2 weeks after completion of antibiotic therapy⁶⁷

Note that infection identified after treatment may well be due to re-infection^{3,66}

Cephalosporin clinical failure following treatment for gonorrhoea

Cases of failure of cephalosporin therapy should be reported to the health protection agency using on-line forms, at the HIV & STI web portal:

https://www.hpaweb services.org.uk/HIV_STI_WebPortal/Login.aspx

Only authorised users are permitted to access this secure website - all GU clinics have been issued with usernames and passwords. Otherwise, they can be obtained from gumcad@hpa.org.uk

Auditable Outcome Measures

- All patients with gonorrhoea should receive first-line treatment or the reasons for not doing so documented
- All patients treated for gonorrhoea should be recommended to have a test of cure
- All patients with gonorrhoea should be screened for genital infection with *Chlamydia trachomatis* or receive presumptive treatment for this infection.
- All patients identified with gonorrhoea should have partner notification carried out according to the published standards of the BASHH Clinical Standards Unit^{68, 69, 70}
- All patients identified with gonorrhoea should be offered written information about sexually transmitted infections and their prevention.

Organisational and Financial Considerations

Whilst the treatments recommended differ in price, they are not expensive and the importance of achieving a cure is so great that cost should not be a factor in choosing the most effective agent.

Clinics managing gonorrhoea should have staffing and facilities allowing the use of injectable antibiotics.

Re-introducing routine test of cure will increase cost but should identify emerging resistant strains, which have the potential to cause much greater health costs.

Qualifying statement

Decisions to follow these recommendations must be based on professional clinical judgement, consideration of individual patient circumstances and available resources. All possible care has been undertaken to ensure specification of the correct dosage of medication and route of administration. However, it remains the responsibility of the prescribing clinician to ensure the accuracy and appropriateness of the medication they prescribe.

Acknowledgments.

We wish to thank the following for their valuable contributions to this Guideline: Professor Cathy Ison and the Gonococcal Resistance to Antimicrobial Surveillance Project group, members of CEG, members of the National Audit Group, and the members of BASHH who made comments during the web-based consultation:

Michael Brady, Sheena Castelino, Gillian Dean, John Evans-Jones, Ben Goh, Philip Hay, Hugo McClean, Jackie Sherrard, Peter Watson, Jeremy Willcox

Authors and Centres.

Chris Bignell, Consultant in Genitourinary Medicine
Nottingham University Hospitals NHS Trust

Mark FitzGerald, Consultant in Genitourinary Medicine, Taunton & Somerset NHS Foundation Trust

Membership of the CEG.

Clinical Effectiveness Group: Chairman, Keith Radcliffe; David Daniels (BASHH National Audit Group); Mark FitzGerald; Margaret Kingston; Neil Lazaro; Gill McCarthy; Ann Sullivan (all are specialist doctors in genitourinary medicine)

Conflict of Interest.

None.

References.

1. Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. *Genitourin Med* 1996; **72**: 422-426.
2. Barlow D, Phillips I. Gonorrhoea in women: diagnostic, clinical and laboratory aspects. *Lancet* 1978; **i**: 761-764.
3. Lewis DA, Bond M, Butt KD, Smith CP, Shafi MS, Murphy SM. A one-year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. *Int J STD AIDS* 1999; **10**: 588-594.
4. Health Protection Agency. All new STI episodes seen at GUM clinics in the UK: 1999-2008.
http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1215589014474
(accessed 10 Feb 2010).
5. Department of Health, Health Protection Agency and BASHH Feb 2010 Guidance for gonorrhoea testing in England and Wales. http://www.bashh.org/news/478_2010-hpa-guidance-on-gonorrhoea-testing. To be published at www.hpa.org.uk
6. Sexually Transmitted Infections: UK National Screening and Testing Guidelines. <http://www.bashh.org/documents/59/59.pdf> (under revision February 2010).
7. Whiley DM, Garland SM, Harnett G, Lum G, Smith DW, Tabrizi SN, et al. Exploring 'best practice' for nucleic acid detection of *Neisseria gonorrhoeae*. *Sexual Health* 2008; **5**: 17-23.

8. Van Dyck E, Ieven M, Pattyn S, Van Damme L, Laga M. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* by enzyme immunoassay, culture and three nucleic acid amplification tests. *J Clin Microbiol* 2001; **39**: 1751-1756.
9. Cook RL, Hutchison SL, Østergaard L, Braithwaite RS, Ness RB. Systematic Review: Non-invasive testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Ann Intern Med* 2005; **142**: 914-925.
10. Martin DH, Cammarata C, Van der Pol B, Jones RB, Quinn TC, Gaydos CA, et al. Multicenter evaluation of AMPLICOR and Automated COBAS AMPLICOR CT/NG tests for *Neisseria gonorrhoeae*. *J Clin Microbiol* 2000; **38**: 3544-3549.
11. Moncada J, Schachter J, Hook EW, Ferrero D, Gaydos C, Quinn T, et al. The effect of urine testing in evaluations of the sensitivity of the Gen-Probe APTIMA Combo 2 Assay on endocervical swabs for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Sex Trans Dis* 2004; **31**: 273-277.
12. Van der Pol B, Ferrero DV, Buck-Barrington L, Hook EIII, Lenderman C, Quinn TC, et al. Multicenter evaluation of the BDProbeTec ET system for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in urine specimens, female endocervical and male urethral swabs. *J Clin Microbiol* 2001; **39**: 1008-1016.
13. Chernesky MA, Martin DH, Hook EW, Willis D, Jordan J, Wang S, et al. Ability of new APTIMA CT and APTIMA GC Assays to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in male urine and urethral swabs. *J Clin Microbiol* 2005; **43**: 127-131.
14. Schachter J, Chernesky MA, Willis DE, Fine PM, Martin DH, Fuller D, et al. Vaginal swabs are the specimens of choice when screening for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*: results from a multicenter evaluation of the APTIMA assays for both infections. *Sex Trans Dis* 2005; **32**: 725-728.
15. Association of Public Health Laboratories. Laboratory diagnostic testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. Expert Consultation Meeting Summary Report; January 13-15, 2009; Atlanta, GA. Silver Spring, MD: Association of Public Health Laboratories; 2009. Available at <http://www.aphl.org/aphlprograms/infectious/std/documents/ctgclabguidelinesmeetingreport.pdf>.
16. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic Acid Amplification Tests in the Diagnosis of Chlamydial and Gonococcal Infections in the Oropharynx and Rectum in Men Who Have Sex With Men. *Sex Trans Dis* 2008; **35**: 637-642.
17. Ota KV, Tamari IE, Smieja M, Jamieson F, Jones KE, Towns L, et al. Detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in pharyngeal

and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. *Sex Trans Infect* 2009; 85: 182-186.

18. Benn PD, Rooney G, Carder C, Brown M, Stevenson SR, Copas A, et al. *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infection and the sexual behaviour of men who have sex with men. *Sex Trans Infect* 2007; 83: 106-112.
19. Page-Shafer K, Graves A, Kent C, Bals JE, Zapitz VM, Klausner JD. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhoea in men who have sex with men. *Clinical Infectious Diseases* 2002; **34**: 173-176.
20. Alexander S. The challenges of detecting gonorrhoea and chlamydia in rectal and pharyngeal sites: could we, should we, be doing more? *Sex Trans Infect* 2009; 85: 159-160.
21. Palmer H, Mallinson H, Wood RL, Herring AJ. Evaluation of the specificities of five DNA amplification methods for the detection of *Neisseria gonorrhoeae*. *J Clin Microbiol* 2003; **41**: 835-837.
22. Health Protection Agency (2010). Detection of *Neisseria gonorrhoeae* using molecular methods. National Standard Method QSOP 62 Issue1. (<http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop62.pdf>)
23. Jephcott AE. Microbiological diagnosis of gonorrhoea. *Genitourin Med* 1997; **73**: 245-252.
24. Katz AR, Effler PV, Ohye RG, et al. False-positive gonorrhoea test results with a nucleic amplification test: the impact of low prevalence on positive predictive value. *Clin Infect Dis* 2004; 38: 814-819.
25. McNally LP, Templeton DJ, Jin F, Grulich AE, Donovan B, Whiley DM, et al. Low positive predictive value of a nucleic acid amplification test for nongenital *Neisseria gonorrhoeae* infection in homosexual men. *Clin Infect Dis* 2008 Jul 15;47(2):e25-e27.
26. Jin F, Prestage GP, Mao L, Kippax SC, Pell CM, Donovan B, et al. Incidence and risk factors for urethral and anal gonorrhoea and Chlamydia in a cohort of HIV-negative homosexual men: the Health in Men study. *Sex Trans Infect* 2007; 83: 113-119.
27. Ghanem M, Radcliffe K, Allan P. The role of urethral samples in the diagnosis of gonorrhoea in women. *Int J STD AIDS* 2004; **15**: 45-47.
28. Lavelle SJ, Jones KE, Mallinson H, Webb AMC. Finding, confirming, and managing gonorrhoea in a population screened for Chlamydia using the Gen-Probe Aptima Combo2 assay. *Sex Trans Infect* 2006; 82: 221-224.
29. FitzGerald M, Bedford C. National standards for the management of gonorrhoea. *Int J STD AIDS* 1996; **7**: 298-300.

30. Newman LM, Moran JS, Workowski KA. Update on the Management of Gonorrhoea in Adults in the United States. *Clin Infect Dis* 2007; **44**: S84-101.
31. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. *Clin Infect Dis* 1995; **20** (suppl 1): S47-65.
32. Moran JS, Zenilman JM. Therapy for gonococcal infections: options in 1989. *Rev Infect Dis* 1990; **12** (suppl 6): S633-644.
33. Tapsall J. Current concepts in the management of gonorrhoea. *Expert Opin Pharmacother.* 2002; 3: 147-157.
34. Ison CA, Mouton JW, Jones K, Fenton KA, Livermore DA. Which cephalosporin for gonorrhoea? *Sex Transm Infect* 2004; **80**: 386-388.
35. Korting HC, Kollman M. Effective single dose treatment of uncomplicated gonorrhoea. *Int J of STD AIDS* 1994; **5**: 239-243.
36. Bignell CJ. Antibiotic treatment of gonorrhoea - clinical evidence for choice. *Genitourin Med* 1996; **72**: 315-320.
37. Echols RM, Heyd A, O' Keeffe BJ, Schacht P. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhoea: a worldwide summary. *Sex Trans Dis* 1994; **21**: 345-352.
38. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. *MMWR* 2006; **55** (No. RR-11): 42-49. (www.cdc.gov/std/treatment).
39. Health Protection Agency. Gonococcal Resistance to Antimicrobial Surveillance Programme (GRASP) Year 2007 Report . http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1221117895841 (accessed 10/02/2010).
40. Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales (GRASP): report of 2009 data *Health Protection Report* Vol 4 No. 34 – 27 August 2010. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245914960426 (accessed 10/02/2010)
41. Martin IMC, Hoffman S, Ison CA. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for *Neisseria gonorrhoeae* in Western Europe. 2006; *J Antimicrob Chemother*; 58: 587-593.
42. Chisholm SA, Neal TJ, Alawattagama AB, Birley HDL, Howe RA, Ison CA. Emergence of high-level azithromycin resistance in *Neisseria gonorrhoeae* in England and Wales. *J Antimicrob Chemother* 2009; 64: 353-8.

43. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. *Euro Surveill.* 2011;**16**(14):p11=19833. Available online <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19833>
44. Forsyth S, Penney P, Rooney G. Cefixime-resistant *Neisseria gonorrhoeae* in the UK: a time to reflect on practice and recommendations. *Int J STD AIDS.* 2011 May;**22**(5):296-7.
45. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant *Neisseria gonorrhoeae*. *Expert Rev Anti Infect Ther* 2009; **7**: 821-834.
46. Chisholm S, Mouton J, Lewis D, Nichols T, Ison C, Livermore D. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? *J Antimicrob Chemother* 2010; **65**: 2141-2148
47. Furuya R, et al. In vitro synergistic effects of double combinations of β -lactams and azithromycin against clinical isolates of *Neisseria gonorrhoeae*. *J Infect Chemotherapy* 2006;**12**:172-6
48. Sathia L, et al. Pharyngeal gonorrhoea – is dual therapy the way forward? *Int J STD AIDS* 2007; **18**: 647-8
49. Lo JYC, Ho KM, Leung AOC, Tiu FST, Tsang GKL, Lo ACT, Tapsall JW. Cefitibuten resistance and treatment failure of *Neisseria gonorrhoeae* infection. *Antimicro Agents Chemother* 2008; **52**: 3564-3567.
50. Novak E, Paxton LM, Tubbs HJ, Turner LF, Keck CW, Yatsu J. Orally administered cefpodoxime proxetil for the treatment of uncomplicated gonococcal urethritis in males: a dose –response study. *Antimicrob Agents Chemther* 1992; **36**: 1764-1765.
51. Tapsall JW. Antibiotic resistance in *Neisseria gonorrhoeae*. *Clin Infect Dis* 2005; **41**: S263-8.
52. Moran JS. Ciprofloxacin for gonorrhea - 250mg or 500mg? *Sex Trans Dis* 1996; **23**: 165-167.
53. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhoea. *Sex Trans Dis* 1994; **21**: 107-111.
54. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant *Neisseria gonorrhoeae* following treatment with azithromycin. *Int J STD AIDS* 1997; **8**: 299-302.

55. Tapsall JW, Schultz TR, Limnios EA, Donovan B, Lum G, Mulhall BP. Failure of azithromycin therapy in gonorrhoea and discorrelation with laboratory parameters. *Sex Trans Dis* 1998; **25**:505-508.
56. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: A meta-analysis. *Otolaryngology-Head and Neck Surgery* (2007); **136**: 340-347.
57. Roche Products Limited. SPC Rocephin. October 2009. <http://emc.medicines.org.uk/medicine/1729/SPC/Rocephin+250mg,+1g+and+2g+vials/> (accessed 05/03/2010).
58. Brocklehurst P. Antibiotics for gonorrhea in pregnancy. *Cochrane Database of Systematic Reviews* 2002, Issue 2. Art. No. CD000098. DOI: 10.1002/14651858.CD000098..
59. Cavenee MR, Farris JR, Spalding TR, Barnes DL, Castaneda YS, Wendel GD. Treatment of gonorrhea in pregnancy. *Obstet Gynecol* 1993; **81**: 33-38.
60. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD. A randomised trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhoea in pregnancy. *Am J Obstet Gynecol* 2001;**185**:629-32.
61. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? *Sex Trans Dis* 1995; **22**: 39-47.
62. Tapsall J, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. *J Med Microbiology* 2009; **58**: 683-687.
63. FitzGerald M, Thirlby D, Bell G, Bedford C. National standards for contact tracing in gonorrhoea. *Int J STD AIDS* 1996; **7**: 301.
64. Society for Sexual Health Advisers. The SSHA manual for sexual health advisers. 2004. Available at <http://www.ssha.info/resources/manual-for-sexual-health-advisers/> (accessed 27 Feb 2010).
65. Holland TM, Hussey J, Pattman RS, Sankar KN, Faldon CM. Audit of gonorrhoea test of cure at the genitourinary medicine department in Newcastle upon Tyne, UK. *Int J STD AIDS* 2003; **14**: 630-631.
66. Komolafe AJ, Sugunendran H, Corkill JE. Gonorrhoea: test of cure for sensitive bacteria? Use of genotyping to disprove treatment failure. *Int J STD AIDS* 2004; **15**: 212.
67. Bachmann LH, Desmond RA, Stephens J, Hughes A, Hook EW 3rd. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhoea. *J Clin Microbiol* 2002; **40**: 3596-601.

68. Low N, Welch J, Radcliffe K. Developing national outcome standards for the management of gonorrhoea and genital chlamydia in genitourinary medicine clinics. *Sex Transm Infect* 2004; **80**: 223-229.
69. Standards for the management of sexually transmitted infections (STIs). Published by Medical Foundation for AIDS & Sexual Health (MedFASH) 2010.
http://www.medfash.org.uk/Projects/BASHH%20standards/Final%20pdfs/Standards_for_the_management_of_STIs.pdf (accessed 05/03/2010).
70. BASHH outcome standards for partner notification in sexually transmitted infections. Document currently in preparation - link to be finalised.